skip to content

Emmaus Life Sciences Brings “Sideline Sickle Cell” Campaign to Dallas for Participation in Annual Warriors Convention

July 24, 2019

Torrance CA, July 24, 2019 - Emmaus Life Sciences, Inc. (“Emmaus”), a leader in sickle cell disease treatment, announced today that the company’s Sideline Sickle Cell campaign, led by Emmy Award-winning NFL broadcaster Solomon Wilcots, will be participating in the 6th Annual Sickle Cell Disease Patient & Family Educational Symposium (Warriors Convention). The event, hosted by the Sickle Cell Community Consortium, is the only national sickle cell disease convention designed, created and hosted by the sickle cell patient and family community.

In addition to hosting activities and discussions at Emmaus Life Sciences’ convention booth, Solomon Wilcots and Charles Stark, Pharm.D., Senior Vice President of Research and Development for Emmaus, will lead an informative presentation at the event’s Young Adult Reception on Thursday, July 25 at 11:00 a.m. This conversation will serve as an opportunity for event participants to learn and ask questions about sickle cell disease and Emmaus’ FDA-approved Endari® (L-glutamine oral powder), used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

Event Details

Location: Hilton Dallas, 5805 Granite Parkway, Plano, TX

Date / Time: July 24 (10:00 a.m. CT) – July 28 (1:00 p.m. CT)

For more information and to register for the convention, please visit:


About Endari® (L-glutamine oral powder)


Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.


Important Safety Information

The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari at:


About Sickle Cell Disease

Sickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded. Patients with sickle cell disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to organ damage, stroke, pulmonary complications, skin ulceration, infection and a variety of other adverse outcomes. Sickle cell disease is a significant unmet medical need, affecting approximately one hundred thousand patients in the U.S. and millions worldwide, the majority of which are of African descent.  An estimated 1-in-365 African-American children is born with sickle cell disease.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.  For more information, please visit

Company Contact:

For Emmaus:

George Sekulich

VP of Commercialization, Emmaus Life Sciences, Inc.



Media Contacts:

David Schull or Caroline Cunningham

Russo Partners

(858) 717-2310